Kindeva Drug Delivery has partnered with Cambridge Healthcare Innovations (CHI) for development and commercialization of CHI’s Aeolus DPI platform, the company said. The Aeolus device is breath-activated, blister-based, and comes in single use, reusable, and multi-unit dose versions. As part of the collaboration, Kindeva will supply product development and regulatory affairs services, as well as manufacturing. Kindeva and CHI say that they plan to evaluate multiple drugs for inhaled delivery via the Aeolus platform and that they are already in partnership discussions with several biopharm companies.
CHI co-founder and Chief Technology Officer David Harris said, “With their unrivaled history and expertise in inhaled drug-delivery, Kindeva is the ideal partner to bring this revolutionary technology to the market. We’re excited to be working together to bring pharmaceutical customers’ products to market faster and at significantly reduced risk, and to offer the unique opportunity to deliver therapies beyond the reach of existing inhalation technology. We’re looking forward to redefining what inhalers can achieve.”
Kindeva CEO Aaron Mann commented, “We are excited to partner with CHI to develop and commercialize a truly novel DPI technology platform. As leaders in inhalation product development, Kindeva understands that the industry must embrace the development of patient-centered technologies in order to meaningfully improve the way patients are treated. The Aeolus technology is designed to avoid many of the drawbacks of existing inhalation technology, addressing the need for efficiency, simplicity, and consistency of delivery, which lead to a more robust patient experience.”
Read the Kindeva Drug Delivery press release.
